Equivalent effects of acute tryptophan depletion on REM sleep in ecstasy users and controls

Psychopharmacology (Berl). 2009 Oct;206(2):187-96. doi: 10.1007/s00213-009-1595-3. Epub 2009 Jul 8.

Abstract

Introduction: This study sought to test the association between 3,4-methylenedioxymethamphetamine use, serotonergic function and sleep.

Materials and methods: Ambulatory polysomnography was used to measure three nights sleep in 12 ecstasy users and 12 controls after screening (no intervention), a tryptophan-free amino acid mixture (acute tryptophan depletion (ATD)) and a tryptophan-supplemented control mixture.

Results: ATD significantly decreased rapid eye movement (REM) sleep onset latency, increased the amount of REM sleep and increased the amount of stage 2 sleep in the first 3 h of sleep. There was no difference between ecstasy users' and controls' sleep on the screening night or after ATD.

Discussion: These findings imply that the ecstasy users had not suffered significant serotonergic damage as indexed by sleep.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Cross-Over Studies
  • Double-Blind Method
  • Hallucinogens / adverse effects
  • Humans
  • N-Methyl-3,4-methylenedioxyamphetamine / adverse effects
  • Pain Measurement
  • Polysomnography / methods
  • Reaction Time / physiology
  • Sleep, REM / drug effects
  • Sleep, REM / physiology*
  • Substance-Related Disorders / metabolism
  • Substance-Related Disorders / physiopathology*
  • Time Factors
  • Tryptophan / administration & dosage
  • Tryptophan / deficiency*
  • Young Adult

Substances

  • Hallucinogens
  • Tryptophan
  • N-Methyl-3,4-methylenedioxyamphetamine